Tilray Brands Strategy: $837M Revenue, But Dilution Shock
Tilray Brands strategy review: $837M revenue, aggressive acquisitions, significant dilution – turnaround opportunity or warning signal?
Eli Lilly Weight Loss +5.2%: Rally Following Study Shock at Novo Nordisk
Eli Lilly Weight Loss: Stock jumps after weaker CagriSema data from Novo Nordisk – what does the rally mean for investors?
Enel Investment Plan Exceeds €53B: Rally Opportunity and Higher Dividend
Enel's €53 billion investment plan, higher dividend, and buyback: How attractive is the stock after the rally?
Salesforce Quarter -4.3%: AI Offensive Between Opportunity and Crash Warning
Salesforce quarter in focus: AI investments, margin pressure, and a stock decline of -4.3% – what’s next for the CRM stock?
NVIDIA Quarter with $66B Revenue: AI Boom or Crash Warning?
NVIDIA quarter expected with $66B revenue: Does the AI boom continue or is a correction looming for investors?
Bitcoin Tariff Shock: Is a Crash to $60,000 Looming Now?
Bitcoin tariff shock pushes BTC to around $66,000 – how real is the slide towards $60,000 support now?
Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.
Apple Tariff Ruling: $3.3B Opportunity and China Risk in Focus
Apple tariff ruling brings billions in potential and margin boost, but China risk and new trade tariffs remain uncertainties.
Merck Dividend Strategy Opportunity: Can It Withstand the Keytruda Patent Shock in 2028?
Merck dividend strategy in focus: Can the pipeline cushion the Keytruda patent cliff starting in 2028 for dividend hunters?
Amazon AI Investments $200B: Opportunity for AWS or Cash Flow Shock?
Amazon's $200B AI investments strain free cash flow—are AWS, advertising, and AI assistants worth the cost?